---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-087950"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:27:32.596221+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Neuphoria 180-day extension to hold annual meeting, cure listing deficiency

## Summary
- Nasdaq accepted compliance plan on Sept 10, 2025; new deadline Dec 29, 2025.
- Deficiency for failure to hold annual meeting within 12 months of fiscal year end June 30, 2024.
- Company plans to file 10-K by Sept 29, 2025, then proxy and hold meeting within extension.
- No financial impact disclosed; listing remains under monitoring.

## SEC filing metadata
- accession: 0001213900-25-087950
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/0001213900-25-087950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/ea0257502-8k_neuphoria.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-087950
- JSON: https://secwatch.observer/filing/0001213900-25-087950.json
- Plain text: https://secwatch.observer/filing/0001213900-25-087950.txt

## Source-grounded claims
- claim_id: 82826ecdc82d41142ae2ca9bd097b4e009e601d5
  claim: Neuphoria Therapeutics Inc. received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).
  evidence_excerpt: September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the “ Compliance Period ”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company’s 2025 annual general shareholder meeting, and further intends to hold such
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/0001213900-25-087950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.